Financing shortfall / going concern pressure
The company expects continued losses and needs new capital to fund operations and trials.
- Scope
- Cash runway, ability to continue as a going concern
- Materiality
- high
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology and its lead product candidate MAT2203. The company is currently centered on advancing MAT2203 toward late-stage development and seeking a partner or transaction to monetize the asset and fund future work.
2.79
2.79
| % | |
|---|---|
| MAT2203 | 70% Lead lipid nanocrystal product candidate being advanced through clinical development and partnership discussions. |
| LNC Platform Technology | 20% Proprietary delivery platform intended to improve formulation, delivery and commercialization potential of drug assets. |
| R&D Services and Development Support | 10% Internal and outsourced research, clinical, CMC and regulatory work supporting pipeline advancement. |
Matinas does not sell commercial pharmaceutical products today; its economic counterparties are primarily potential...
- Pharmaceutical partnership candidatesprimary
Large or well-funded biotech/pharma companies that could license MAT2203 and fund Phase 3 development and commercialization.
- Strategic licensing counterpartiesprimary
Companies evaluating the LNC platform or related assets for non-dilutive licensing or acquisition.
- Clinical research vendorssecondary
CROs, laboratories and consultants that provide trial design, execution, analysis and regulatory support.
- Government and third-party funding sourcessecondary
NIH and other non-dilutive funding providers that may support preclinical or clinical work.
The company is headquartered in the United States and its disclosed operating footprint is centered on U.S...
- •Headquartered in the United States
- •R&D and regulatory work are primarily U.S.-based
- •Clinical studies may involve U.S. CROs and NIH support
- •No meaningful commercial geography yet disclosed
- •Future partner commercialization could expand global reach
Matinas is prioritizing a partnership or licensing transaction for MAT2203 to secure non-dilutive capital and...
01
Partner MAT2203short-term
A funded partner can advance the asset faster and reduce Matinas' capital burden.
02
Preserve liquidityshort-term
The company is loss-making and needs to extend runway while it seeks strategic options.
03
Broaden strategic optionalitymedium-term
Additional assets or a merger could create value if MAT2203 monetization is delayed.
Matinas is a pre-revenue biotech with a high dependence on external financing and successful partnering of MAT2203...
MAT2203 development failure or delay
Value creation depends heavily on advancing the lead candidate into Phase 3 and beyond.
- Scope
- Pipeline concentration
- Materiality
- high
Partnering and licensing execution risk
The strategy relies on finding a capable third-party partner on acceptable terms.
- Scope
- Monetization of lead asset
- Materiality
- high
Dilution from equity financings
Management may need to issue common stock or convertible securities to raise funds.
- Scope
- Shareholder ownership and capital structure
- Materiality
- high
Warrant and preferred stock complexity
Recent financings included warrants and preferred stock that can affect reported earnings and dilution.
- Scope
- Valuation and share count
- Materiality
- medium
Warrant liability fair value
Can materially move other income/expense and net loss
Research and development expense timing
Affects operating loss and quarter-to-quarter comparability
Goodwill and intangible impairment
Potential non-cash write-downs
Stock-based compensation
Raises operating expenses without cash outflow
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
INTEGRATED BIOPHARMA INC
INBP · Pharmaceutical Preparations
IONIS PHARMACEUTICALS INC
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Citius Pharmaceuticals, Inc.
CTXR · Pharmaceutical Preparations
Liminatus Pharma, Inc.
LIMN · Biological Products, (No Diagnostic Substances)
: 28.4.2026